DATROWAY launched in Japan as the first TROP2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer

CAR-T Digest - August 2020

Weekly Digest - March 2025

19 Mar 2025: DATROWAY launched in Japan as the first TROP2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer

DATROWAY (datopotamab deruxtecan) has been launched in Japan for HR positive, HER2 negative unresectable, or recurrent breast cancer after prior chemotherapy
It is the first TROP2-directed therapy available in Japan and the second DXd antibody-drug conjugate using Daiichi Sankyo’s DXd technology
Approval was granted by Japan’s Ministry of Health, Labour and Welfare in December 2024, based on the TROPION-Breast01 Phase 3 trial results
DATROWAY significantly reduced the risk of disease progression or death by 37% compared to chemotherapy, with a median progression-free survival of 6.9 months
The treatment comes with a warning for interstitial lung disease (ILD) and requires close monitoring for early signs of ILD during therapy